Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
ATAZANAVIRSULFAAT SAMENSTELLING overeenkomend met ; ATAZANAVIR
Alvogen Malta Operations (ROW) Ltd. Malta Life Sciences Park, Building 1, Level 4, Sir Temi Zammit Buildings SGN 3000 SAN GW
J05AE08
ATAZANAVIRSULFAAT COMPOSITION corresponding to ; ATAZANAVIR
Capsule, hard
CROSPOVIDON (E 1202) ; GELATINE (E 441) ; INDIGOKARMIJN (E 132) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; PROPYLEENGLYCOL (E 1520) ; SCHELLAK (E 904) ; SILICIUMDIOXIDE (E 551) ; TITAANDIOXIDE (E 171) ; WITTE INKT
Oraal gebruik
Atazanavir
2018-11-09
39 PACKAGE LEAFLET: INFORMATION FOR THE USER ATAZANAVIR ALVOGEN 150 MG HARDE CAPSULES ATAZANAVIR ALVOGEN 200 MG HARDE CAPSULES ATAZANAVIR ALVOGEN 300 MG HARDE CAPSULES Atazanavir READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. Whatis and what it is used for 2. What you need to know before you take Lees het volledige document3. How to take 4. Possible side effects 5 How to store 6. Contents of the pack and other information 1. WHAT IS AND WHAT IT IS USED FOR IS AN ANTIVIRAL (OR ANTIRETROVIRAL) MEDICINE. It is one of a group called _protease_ _ _ _inhibitors_ . These medicines control Human Immunodeficiency Virus (HIV) infection by stopping a protein that the HIV needs for its multiplication. They work by reducing the amount of HIV in your body and this in turn, strengthens your immune system. In this way reduces the risk of developing illnesses linked to HIV infection. capsules may be used by adults and children 6 years of age and older. Your doctor has prescribed for you because you are infected by the HIV that causes Acquired Immunodeficiency Syndrome (AIDS). It is normally used in combination with other anti-HIV medicines. Your doctor will discuss with you which combination of these medicines with is best for you. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE DO NOT TAKE - IF YOU ARE ALLERGIC to atazanavir or any of the other ingredients of this medici
1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Atazanavir Alvogen 150 mg, harde capsules
Atazanavir Alvogen 200 mg, harde capsules
Atazanavir Alvogen 300 mg, harde capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ 100 mg hard capsules: _
Each capsule contains 100 mg of atazanavir (as sulfate).
Excipient with known effect
46.00 mg of lactose monohydrate per capsule.
_ 150 mg hard capsules: _
Each capsule contains 150 mg of atazanavir (as sulfate).
Excipient with known effect
69.00 mg of lactose monohydrate per capsule.
_ 200 mg hard capsules: _
Each capsule contains 200 mg of atazanavir (as sulfate).
Excipient with known effect
92.00 mg of lactose monohydrate per capsule.
_ 300 mg hard capsules: _
Each capsule contains 300 mg of atazanavir (as sulfate).
Excipient with known effect
138.00 mg of lactose monohydrate per capsule.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule
_ 100 mg hard capsules: _
Opaque, blue and white capsule of size 2 printed with white ink, with
“100 mg” on the cap.
_ 150 mg hard capsules: _
Opaque, blue and powder blue capsule of size 1 printed with white ink,
with “150 mg” on the cap.
_ 200 mg hard capsules: _
Opaque, blue capsule of size 0 printed with white ink, with “200
mg” on the cap.
_ 300 mg hard capsules: _
Opaque red and blue capsule of size 00 printed with white ink, with
“300 mg” on the cap.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
capsules, co-administered with low dose ritonavir, are
indicated for the treatment of
HIV-1 infected adults and paediatric patients 6 years of age and older
in combination with other
antiretroviral medicinal products (see section 4.2).
Based on available virological and clinical data from adult patients,
no benefit is expected in patients
with strains resistant to multiple protease inhibitors (≥ 4 PI
mutations).
2
The choice of
Lees het volledige document